Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

JE00BYSS4X48
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG009XW8PY2
NVCR
Novocure Ltd
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Medical Instruments & Supplies · THEMEFOLIO: $HLTH
NAME
Novocure Ltd
ISIN
JE00BYSS4X48
TICKER
NVCR
MIC
XNAS
REUTERS
NVCR.OQ
BLOOMBERG
NVCR US
Sat, 20.06.2026       NovoCure
JE00BYSS4X48

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of NovoCure Limited (“NovoCure” or “the Company”) (NASDAQ: NVCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to di...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Fri, 19.06.2026       NovoCure
JE00BYSS4X48

Novocure reported its Phase 3 TRIDENT Trial failed to achieve its primary endpoint of an increase in overall survival for patients at the start of chemoradiation. Shares were down more than 18% midday on June 18, 2026. NEW YORK,, June 18, 2026 /PRNewswire/ -- Investors who held Novocure Limited (NASDAQ: NVCR) shares lost more than $3 per share on...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Thu, 18.06.2026       NovoCure
JE00BYSS4X48

Novocure (NASDAQ: NVCR) announced topline results today from its Phase 3 TRIDENT trial, which evaluated the initiation of Tumor Treating Fields (TTFields) therapy for newly diagnosed glioblastoma (GBM) at the start of chemoradiation (Early Start Arm) compared to initiating TTFields therapy during the subsequent maintenance phase of treatment (Main...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Thu, 30.04.2026       NovoCure
JE00BYSS4X48

Novocure (NASDAQ: NVCR) today reported financial results for the first quarter that ended March 31, 2026. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). “This was a very strong start to the...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Wed, 01.04.2026       NovoCure
JE00BYSS4X48

Novocure (NASDAQ: NVCR) will report financial results for the first quarter 2026 on April 30, 2026, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, April 30, to discuss the company’s financial results for the three-month period that ended March 31, 2026. To access the confer...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Thu, 26.03.2026       NovoCure
JE00BYSS4X48

Novocure (NASDAQ: NVCR) announced positive results today from the Phase 2 PANOVA-4 trial of Tumor Treating Fields (TTFields) therapy concomitant with atezolizumab (Tecentriq®), gemcitabine and nab-paclitaxel (gem/nab-pac) as a first-line treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC). PANOVA-4 met its pre-specified primary end...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Mon, 02.03.2026       NovoCure
JE00BYSS4X48

Novocure (NASDAQ: NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare approved reimbursement for Optune Lua® through the country’s National Health Insurance coverage. Optune Lua is approved in Japan for concurrent use with PD-1/PD-L1 inhibitors in adult patients with unresectable advanced/recurrent NSCLC who progressed on o...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Fri, 27.02.2026       NovoCure
JE00BYSS4X48

Novocure (NASDAQ: NVCR) announced today that management will participate in the Leerink Global Healthcare Conference on Tuesday, March 10, 2026. Frank Leonard, Chief Executive Officer, and Christoph Brackmann, Chief Financial Officer, will take part in a fireside chat at 11:20 a.m. EST, as well as one-on-one meetings with investors throughout the...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Thu, 26.02.2026       NovoCure
JE00BYSS4X48

Novocure (NASDAQ: NVCR) today reported financial results for the quarter and full year ended December 31, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). “In 2025, a record number of pa...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Tue, 24.02.2026       NovoCure
JE00BYSS4X48

Novocure (NASDAQ: NVCR) announced today that the province of British Columbia, Canada, will now cover Tumor Treating Fields (TTFields) therapy for the treatment of adult patients with newly diagnosed glioblastoma. British Columbia is the first province to provide coverage following Canada’s Drug Agency’s assessment and reimbursement recommendation...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Wed, 11.02.2026       NovoCure
JE00BYSS4X48

Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) approved Optune Pax® for the treatment of adult patients with locally advanced pancreatic cancer concomitant with gemcitabine and nab-paclitaxel. “In the Phase 3 PANOVA-3 trial, treatment with Optune Pax resulted in a statistically significant improvement in...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Mon, 12.01.2026       NovoCure
JE00BYSS4X48

Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial and operational results for the quarter and full year ended December 31, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFiel...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Mon, 22.12.2025       NovoCure
JE00BYSS4X48

Novocure (NASDAQ: NVCR) announced today that management will participate in the 44th Annual J.P. Morgan Healthcare Conference taking place in San Francisco on January 12-15, 2026. Frank Leonard, Chief Executive Officer, will present on behalf of the company and address questions on Wednesday, January 14, at 9:45 a.m. PST. Mr. Leonard will be joine...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Mon, 01.12.2025       NovoCure
JE00BYSS4X48

Novocure (NASDAQ: NVCR) today announced the appointment of Frank Leonard as Chief Executive Officer (CEO), effective immediately. Mr. Leonard previously served as President of Novocure and succeeds Ashley Cordova who has resigned from the company. “During his more than 15-year career at Novocure, Frank has led many of our global business operatio...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Wed, 26.11.2025       NovoCure
JE00BYSS4X48

Novocure (NASDAQ: NVCR) announced today that management will participate in the 37th Annual Piper Sandler Healthcare Conference in New York on Tuesday, December 2, 2025. William Doyle, Novocure’s Executive Chairman, will take part in a fireside chat at 11:30 a.m. ET, as well as one-on-one meetings with investors throughout the event. A live audio...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Wed, 12.11.2025       NovoCure
JE00BYSS4X48

Novocure (NASDAQ: NVCR) announced today that management will participate in the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025. Ashley Cordova, Chief Executive Officer, will present on behalf of the company at 2:00 p.m. GMT (9:00 a.m. ET). Ms. Cordova will be joined by Christoph Brackmann, Chief Financial Officer,...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Thu, 30.10.2025       NovoCure
JE00BYSS4X48

Novocure (NASDAQ: NVCR) today reported financial results for the third quarter that ended September 30, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). “Q3 was a solid quarter with stea...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Wed, 15.10.2025       NovoCure
JE00BYSS4X48

Novocure (NASDAQ: NVCR) announced today that it will present data at two upcoming oncology congresses, the 2025 European Association of Neuro-Oncology (EANO) Meeting, being held October 16-19 in Prague, Czech Republic, and the European Society for Medical Oncology (ESMO) Congress 2025, being held October 17-21 in Berlin, Germany. At the EANO 202...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Wed, 01.10.2025       NovoCure
JE00BYSS4X48

Novocure (NASDAQ: NVCR) will report financial results for the third quarter 2025 on October 30, 2025, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, October 30, to discuss the company’s financial results for the three- and nine-month periods that ended September 30, 2025. T...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Mon, 29.09.2025       NovoCure
JE00BYSS4X48

Novocure (NASDAQ: NVCR) announced that final results from the Phase 3 METIS trial of Tumor Treating Fields (TTFields) therapy for brain metastases from non-small cell lung cancer (NSCLC) will be presented today at the 2025 American Society for Radiation Oncology (ASTRO) Annual Meeting taking place September 27 – October 1 in San Francisco and simu...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Mon, 15.09.2025       NovoCure
JE00BYSS4X48

Novocure (NASDAQ: NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Optune Lua® for concurrent use with PD-1/PD-L1 inhibitors for the treatment of adult patients with unresectable advanced/recurrent non-small cell lung cancer (NSCLC) who have progressed on or after platinum-based chemotherapy. “With the Mi...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Thu, 28.08.2025       NovoCure
JE00BYSS4X48

Novocure (NASDAQ: NVCR) announced today that management will participate in three upcoming investor events. 2025 Wells Fargo Healthcare Conference, September 4, 2025: Ashley Cordova, Chief Executive Officer, will take part in a fireside chat at 9:30 a.m. ET, as well as one-on-one meetings with investors throughout the event. H.C. Wainwright...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Mon, 25.08.2025       NovoCure
JE00BYSS4X48

Novocure (NASDAQ: NVCR) announced today that Spain’s Ministry of Health has made Tumor Treating Fields (TTFields) therapy available through the Spanish National Health System (SNS) for the treatment of adult patients with newly diagnosed glioblastoma. “Glioblastoma is one of the most common and aggressive forms of primary brain cancer with few t...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Wed, 20.08.2025       NovoCure
JE00BYSS4X48

Novocure (NASDAQ: NVCR) today announced it submitted a premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for Tumor Treating Fields (TTFields) therapy for the treatment of locally advanced pancreatic cancer. This submission is supported by the PANOVA-3 trial, which evaluated the use of TTFields therapy concomitan...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Thu, 24.07.2025       NovoCure
JE00BYSS4X48

Novocure (NASDAQ: NVCR) today reported financial results for the second quarter that ended June 30, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). “With the first half of 2025 complete...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Tue, 01.07.2025       NovoCure
JE00BYSS4X48

Novocure (NASDAQ: NVCR) announced today that it will present the final secondary endpoint results from the Phase 3 PANOVA-3 trial of its Tumor Treating Fields (TTFields) therapy for unresectable, locally advanced pancreatic cancer. These data from PANOVA-3 were accepted as a late-breaking abstract for oral presentation at the European Society for...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Mon, 30.06.2025       NovoCure
JE00BYSS4X48

Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2025 on July 24, 2025, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, July 24, to discuss the company’s financial results for the three- and six-month periods that ended June 30, 2025. To access th...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Sat, 31.05.2025       NovoCure
JE00BYSS4X48

Novocure (NASDAQ: NVCR) announced that results from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer will be presented today at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and simultaneously published in the Journal of Clinical Oncology. “The data presented today fro...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Tue, 27.05.2025       NovoCure
JE00BYSS4X48

Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor events. PANOVA-3 Investor Event, May 31, 2025: Novocure will host investors on Saturday, May 31 at 8:00 p.m. ET / 7:00 p.m. CT in Chicago to review data from the successful Phase 3 PANOVA-3 clinical trial in unresectable, locally advanced pancreati...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Thu, 24.04.2025       NovoCure
JE00BYSS4X48

Novocure (NASDAQ: NVCR) today reported financial results for the first quarter ended March 31, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). “This is a period of meaningful momentum fo...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Wed, 23.04.2025       NovoCure
JE00BYSS4X48

Novocure (NASDAQ: NVCR) announced today that it will present additional results from the Phase 3 PANOVA-3 trial of its Tumor Treating Fields (TTFields) therapy for pancreatic cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 to June 3 in Chicago. The PANOVA-3 trial evaluated the use of TTFields th...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Tue, 22.04.2025       NovoCure
JE00BYSS4X48

Novocure (NASDAQ: NVCR) announced today that Optune Lua® has received a CE (Conformité Européenne) Mark for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) concurrently with immune checkpoint inhibitors or docetaxel who have progressed on or after a platinum-based regimen. “Optune Lua is an innovative and urgent...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Tue, 01.04.2025       NovoCure
JE00BYSS4X48

Novocure (NASDAQ: NVCR) will report financial results for the first quarter 2025 on April 24, 2025, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, April 24, to discuss the company’s financial results for the three-month quarter that ended March 31, 2025. To access the conferen...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Tue, 04.03.2025       NovoCure
JE00BYSS4X48

Novocure (NASDAQ: NVCR) announced today that management will participate in the Leerink Global Healthcare Conference on Tuesday, March 11, 2025. Christoph Brackmann, Chief Financial Officer, will take part in a fireside chat at 4:20 p.m. EST, as well as one-on-one meetings with investors throughout the event. A live audio webcast of this present...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Thu, 27.02.2025       NovoCure
JE00BYSS4X48

Novocure (NASDAQ: NVCR) today reported financial results for the quarter and full year ended December 31, 2024. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). “Entering 2024, our team was fo...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Wed, 22.01.2025       NovoCure
JE00BYSS4X48

Novocure (NASDAQ: NVCR) announced today the official opening of its new global headquarters in the Canton of Zug, Switzerland. Novocure is an oncology company working to extend survival in some of the most aggressive forms of cancer, through the development and commercialization of its innovative therapy, Tumor Treating Fields (TTFields). The co...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Mon, 13.01.2025       NovoCure
JE00BYSS4X48

Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial and operational results for the quarter and full year ended December 31, 2024. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFiel...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Fri, 03.01.2025       NovoCure
JE00BYSS4X48

Novocure (NASDAQ: NVCR) announced today that management will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025. Ashley Cordova, Chief Executive Officer, and William Doyle, Executive Chairman, will speak on behalf of the company and address questions at 9:00 a.m. PST. Ms. Cordova and Mr. Doyle will be j...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Mon, 02.12.2024       NovoCure
JE00BYSS4X48

Novocure (NASDAQ: NVCR) announced today that the pivotal, Phase 3 PANOVA-3 trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival (mOS) versus control. PANOVA-3 evaluated the use of Tumor Treating Fields (TTFields) therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line tr...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Wed, 27.11.2024       NovoCure
JE00BYSS4X48

Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor conferences: Evercore ISI HealthCONx Conference on Wednesday, December 4, 2024, in Coral Gables, Florida. William Doyle, Executive Chairman, will take part in a fireside chat at 2:10 p.m. ET. Piper Sandler Healthcare Conference on Thursday, Dec...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Thu, 21.11.2024       NovoCure
JE00BYSS4X48

Novocure (NASDAQ: NVCR) announced today that it will present new data for its Tumor Treating Fields (TTFields) therapy for glioblastoma at the 29th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO), November 21 – 24, Houston, Texas. Novocure will present the results of its work to design arrays that will allow e...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Thu, 21.11.2024       NovoCure
JE00BYSS4X48

Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) approved its new Head Flexible Electrode (HFE) transducer arrays for use with Optune Gio® for the treatment of adult patients with glioblastoma multiforme (GBM). Optune Gio is a wearable, portable device that produces alternating electric fields known as Tum...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Wed, 30.10.2024       NovoCure
JE00BYSS4X48

Novocure (NASDAQ: NVCR) announced today that Christoph Brackmann has been appointed as the company’s next Chief Financial Officer (CFO). Mr. Brackmann will join Novocure immediately as a Senior Financial Advisor and will transition to the role of CFO on January 1, 2025 when current CFO, Ashley Cordova, becomes CEO. Mr. Brackmann joins Novocure fr...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Wed, 30.10.2024       NovoCure
JE00BYSS4X48

Novocure (NASDAQ: NVCR) today reported financial results for the third quarter ended September 30, 2024. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). “This was a period of strong execution...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Tue, 15.10.2024       NovoCure
JE00BYSS4X48

Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for concurrent use with PD-1/PD-L1 inhibitors or docetaxel, for the treatment of adult patients with metastatic non-small cell lung cancer (mNSCLC) who have progressed on or after a platinum-based regimen. “Novocure is committed to ex...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Tue, 01.10.2024       NovoCure
JE00BYSS4X48

Novocure (NASDAQ: NVCR) will report financial results for the third quarter 2024 on Wednesday, October 30, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, October 30, to discuss the company’s financial results for the three-month quarter and first nine months of the year t...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Mon, 09.09.2024       NovoCure
JE00BYSS4X48

Novocure (NASDAQ: NVCR) announced today it will present a real-world analysis of usage of its Tumor Treating Fields (TTFields) therapy and survival outcomes in newly diagnosed glioblastoma (ndGBM) patients at the European Society for Medical Oncology (ESMO) Congress 2024, September 13 – 17, Barcelona, Spain. The results of the real-world analysis...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Tue, 03.09.2024       NovoCure
JE00BYSS4X48

Novocure (NASDAQ: NVCR) announced today that Chief Executive Officer (CEO), Asaf Danziger, will retire at year-end 2024 and Novocure’s Chief Financial Officer (CFO), Ashley Cordova, will succeed him as the company’s next CEO. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240903420700/...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Wed, 28.08.2024       NovoCure
JE00BYSS4X48

Novocure (NASDAQ: NVCR) announced today that management will participate in the 2024 Wells Fargo Healthcare Conference on Wednesday, September 4, 2024. William Doyle, Novocure’s Executive Chairman, will take part in a fireside chat at 4:30 p.m. EST, as well as one-on-one meetings with investors throughout the event. A live audio webcast of this...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink
Wed, 14.08.2024       NovoCure
JE00BYSS4X48

Novocure (NASDAQ: NVCR) today announced its participation in the upcoming International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer (WCLC) from September 7 – 10, 2024 in San Diego, California. Novocure will take part in presentations and symposia throughout the event and will exhibit several posters explor...
Read more
NovoCure
Technical Analysis Termsheets Terminal
Permalink